Orion Oyj (OTCMKTS:ORINY) Hits New 52-Week High - Time to Buy?

Orion Oyj (OTCMKTS:ORINY - Get Free Report) shares reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $30.57 and last traded at $30.57, with a volume of 306 shares. The stock had previously closed at $29.76.

Analyst Ratings Changes

Separately, Nordea Equity Research lowered Orion Oyj to a "hold" rating in a research note on Tuesday, February 4th.

Orion Oyj Stock Performance

The company has a fifty day simple moving average of $27.42 and a two-hundred day simple moving average of $25.58. The company has a current ratio of 2.42, a quick ratio of 1.41 and a debt-to-equity ratio of 0.25. The company has a market cap of $8.63 billion, a PE ratio of 24.26 and a beta of 0.25.

Orion Oyj (OTCMKTS:ORINY - Get Free Report) last released its quarterly earnings data on Tuesday, February 25th. The company reported $0.28 EPS for the quarter. Orion Oyj had a return on equity of 39.49% and a net margin of 23.01%. The business had revenue of $463.41 million for the quarter. Analysts anticipate that Orion Oyj will post 1.18 EPS for the current year.

Orion Oyj Increases Dividend

The company also recently declared a dividend, which will be paid on Tuesday, April 29th. Investors of record on Monday, April 7th will be paid a dividend of $0.4478 per share. The ex-dividend date is Monday, April 7th. This is an increase from Orion Oyj's previous dividend of $0.24. Orion Oyj's dividend payout ratio (DPR) is currently 24.00%.

Remove Ads

Orion Oyj Company Profile

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.